ArticleBMJ open gastroenterology2025
Current and projected incidence rates of pancreatic cancer in 43 countries: an analysis of the Cancer Incidence in Five Continents database.
Article in BMJ open gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?International journal of molecular sciences · 2026Pooled it
- Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.Nature medicine · 2026Article
- Mobile Usage Duration and Usability of Mobile Health Applications Among Older Adults in Saudi Arabia: A Usability-Centered Model Informed by Technology Acceptance Theory.Healthcare (Basel, Switzerland) · 2026Article
- Nootkatone as a multi-target modulator of the PD-L1/PD-1 signaling in pancreatic cancer: network pharmacology, docking, molecular dynamics, and DFT analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Distinct Inflammatory and Dissemination Signatures Defined by Macrophage Migration Inhibitory Factor (MIF), Interleukin-8 (IL-8/CXCL8), and Stem Cell Factor (SCF) in Pancreatic Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Effects of Proglumide with Chemotherapy on the Pancreatic Tumor Microenvironment: Phase 1 PROGEM Trial.Pharmaceutics · 2026Article
- Global Burden and Future Trends of Gastrointestinal Cancers in Adolescents and Young Adults, 1990-2045: A Predictive Analysis.Journal of gastrointestinal cancer · 2026Article
- Conversion and resection rates in borderline resectable and locally advanced pancreatic cancer following neoadjuvant therapy: a retrospective multicenter cohort study.Frontiers in oncology · 2026Article
- Survival rate in patients with pancreatic cancer in Guilan province, Iran.Caspian journal of internal medicine · 2026Article
- Endoscopic ultrasound-guided radiofrequency ablation of pancreatic tumors: Current status and future perspectives.World journal of methodology · 2025Review
- Inflammatory biomarkers in the pathogenesis of pancreatic cancer: A literature review.World journal of clinical oncology · 2025Review
- Pancreatic Cancer in High-Income Asia-Pacific: A Population-Based Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aetiology of pancreatic cancer is complex, and there is limited research on its incidence. We aimed to investigate the incidence trends of pancreatic cancer in 43 countries and predict trends up to 2030.
methodsThe annual incidence of pancreatic cancer was obtained from the Cancer Incidence in Five Continents database, which comprises 108 cancer registries from 43 countries. Based on available data, we calculated age-standardized incidence rates (ASRs) per 100 000 people for 1988-2012. A Bayesian age-period-cohort model was used to predict the number of new cases and incidence rates up to 2030.
resultsFrom 1988 to 2012, the global incidence rate of pancreatic cancer showed a continuously increasing trend, with the ASR increasing from 5.89 in 1988 to 6.78 in 2012, representing an overall average annual percentage change of 8.45%. This increasing trend is expected to persist in most selected countries, whereas a few countries are projected to exhibit a declining trend by 2030.
conclusionIt appears that the future global incidence of pancreatic cancer is on the rise, but the rate of increase varies among different countries, with some showing a declining trend.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.